ICD-10 · PDGM grouping
Q85 Phakomatoses, not elsewhere classified
All 11 codes in the Q85 family, with the PDGM clinical group, comorbidity subgroup and primary-position rule CMS assigns, read from the CMS grouper crosswalk v07.2.26 and the CDC FY2027 code file.
Codes in family
11
Can lead a claim
11
Cannot lead a claim
0
What CMS assigns to Q85
All 11 codes group to MMTA - Other (6) and Neuro Rehabilitation (5). None of the 11 is assigned a comorbidity subgroup. Every code can lead a claim.
Every code in Q85
Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.
| Code | Description | Primary position | Clinical group | Comorbidity subgroup |
|---|---|---|---|---|
| Q85.0 Neurofibromatosis (nonmalignant) | ||||
| Q85.00 | Neurofibromatosis, unspecified | Can lead a claim | B | None |
| Q85.01 | Neurofibromatosis, type 1 | Can lead a claim | B | None |
| Q85.02 | Neurofibromatosis, type 2 | Can lead a claim | B | None |
| Q85.03 | Schwannomatosis | Can lead a claim | B | None |
| Q85.09 | Other neurofibromatosis | Can lead a claim | B | None |
| Q85.1 | Tuberous sclerosis | Can lead a claim | A | None |
| Q85.8 Other phakomatoses, not elsewhere classified | ||||
| Q85.81 | PTEN hamartoma tumor syndrome | Can lead a claim | A | None |
| Q85.82 | Other Cowden syndrome | Can lead a claim | A | None |
| Q85.83 | Von Hippel-Lindau syndrome | Can lead a claim | A | None |
| Q85.89 | Other phakomatoses, not elsewhere classified | Can lead a claim | A | None |
| Q85.9 | Phakomatosis, unspecified | Can lead a claim | A | None |
Sources: CMS HH PPS Grouper Software v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.
The monthly home health regs digest
What CMS changed, what's due next, and what to do about it — one email a month, no fluff. Read the first issue